– UK, Slough – Indivior PLC (LON: INDV) today announced the appointments to its Board of Juliet Thompson, Jo Le Couilliard, and Mark Stejbach as independent Non-Executive Directors, and of Jerome Lande, a Partner of Scopia Capital Management LP, as Non-Executive Director.
- Ms. Thompson provides a valuable combination of experience as an FTSE 250 audit chair and as a former investment banker who has spent her career advising pharmaceutical companies.
- Ms. Le Couilliard possesses extensive experience with managing and transforming commercial models in the pharma sector.
- Mr. Stejbach brings valuable first-hand experience with profitably growing novel treatments, with particular experience in those targeting substance use disorders.
- Mr. Lande provides extensive investment expertise in the healthcare sector.
The Company also announced today that following a period of constructive dialogue, it has today entered into a relationship agreement with its largest shareholder, Scopia Capital Management LP, that will see Indivior benefit from Scopia’s insight and perspectives as an experienced healthcare investor.
“After a period of significant strategic change and decisive actions to better position Indivior for future value creation, we are looking to realize the full transformational potential of SUBLOCADE over the coming years. Building on this momentum, we are pleased to welcome the new NEDs to the Board and unanimously recommend that shareholders vote in favor of their appointment at the forthcoming 2021 Annual General Meeting of Shareholders on May 6th 2021.” said Board Chair, Graham Hetherington.
He added: “Subject to election by shareholders at the 2021 AGM, Indivior’s Board will comprise 11 directors who together offer expertise in a wide range of relevant fields, including commercial excellence, science, and policy, medicines development, as well as audit, risk, and financial expertise. All of these capabilities are critical in driving the long-term success of Indivior and in delivering value to shareholders. The Board is committed to further enhancing its diversity and experience. In assessing potential candidates for the outstanding NED position, particular attention is being paid to improving the gender diversity of the Board.
“Indivior’s Board and leadership team are committed to engaging actively with shareholders to better understand their views and we fully support and look forward to Jerome’s perspectives as a representative of our largest shareholder”.
As previously announced, Daniel Tassé, current Senior Independent Director, will not stand for re-election at the Company’s 2021 AGM and will stand down after that meeting. The Board has identified Dan Phelan as the most qualified Independent Director to take on the role of Senior Independent Director with effect from the conclusion of the 2021 AGM.
About Juliet Thompson
Juliet Thompson has over 30 years of finance, banking, and board experience with a significant focus in the healthcare sector. Juliet Thompson is a proven FTSE 250 audit chair and a former investment banker who has spent her career advising pharmaceutical companies. She played a leading role in setting up Code Securities, which was quickly acquired by Nomura (becoming Nomura Code) but remained independent. At Nomura Code, Juliet was advising companies in the healthcare and cleantech sectors on their financing and strategic options. She worked on over 50 transactions including IPO’s, secondary offerings, private placements, and M&A. As Nomura Code was devolved, she joined Stifel with a team from Nomura Code to head up the life sciences and cleantech teams where she advised CEOs and CFOs in the healthcare sector. Since retiring, Juliet has built a diverse portfolio and currently chairs the Audit Committees of Novacyt and Vectura. She is also a Non-Executive Director of Organox. She previously served on the Board of GI Dynamics, a Boston-based medical device company developing products for patients with type 2 diabetes and obesity.
She holds a BSc in Economics from the University of Bristol and is a Chartered Accountant holding an ACA from the Association of Chartered Certified Accountants.
About Joanna Le Couilliard
Joanna Le Couilliard is a healthcare industry veteran who spent the majority of her career in general management, finance, and commercial roles for leading pharmaceutical companies. Ms. Le Couilliard retired in 2018 as part of GlaxoSmithKline’s Global Pharmaceuticals leadership team, where she was responsible for transforming GSK’s commercial model through building digital, data, and analytics capability across GSK. While at GSK, she was also responsible for the Asia Pacific region. Before that, Ms. Le Couilliard served as Chief Operating Officer at the BMI group of private hospitals in the UK. She currently serves as a Non-Executive Director and Chair of the Audit, Risk and Nomination Committee at Circassia Pharmaceuticals plc, a Non-Executive Director at Alliance Pharma plc, and a Non-Executive Director at the Italian listed pharmaceutical company, Recordati S.p.A., where she is Chair of the Remuneration Committee. She has previously served as a Non-Executive Director at Frimley Park NHS Foundation Trust in the UK, Cello Health PLC, and at the Duke NUS Medical School in Singapore.
Ms. Le Couilliard is a Chartered Accountant holding an ACA from the Association of Chartered Certified Accountants and holds a Masters in Natural Sciences from the University of Cambridge.
About Mark Stejbach
Mark Stejbach has over 30 years of experience in biotech and pharmaceuticals, including senior roles in a broad range of commercial functions including marketing, sales, economic affairs, managed care, and finance. Mr. Stejbach most recently served as SVP and Chief Commercial Officer at Alkermes, plc, a publicly-traded global biopharmaceutical company, where he was responsible for building sales of Vivitrol from ~$40m to ~$300m. Before his role at Alkermes, Mr. Stejbach served as the Chief Commercial Officer at Tengion, Inc. from 2008 to 2012, and he previously held senior positions at Merck and Biogen. He currently serves as a non-executive on the board of Flexion Therapeutics (NASDAQ: FLXN), which has recently launched a “buy-and-bill,” long-acting injectable for the treatment of osteoarthritis. He previously served as Senior Commercial Advisor to EIP Pharma Inc., a private company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases.
Mark Stejbach holds an M.B.A. from the Wharton School, the University of Pennsylvania, and a B.S. in mathematics from Virginia Tech.
About Jerome Lande
Jerome Lande has over 20 years of experience as a professional investor, including substantial investing in medical device, pharmaceutical, and healthcare services companies. He currently serves as Head of Special Situations investments at Scopia Capital Management. Mr. Lande co-founded Coppersmith Capital Management, where he was managing partner and portfolio manager until it combined with Scopia in 2016. Before co-founding Coppersmith, Mr. Lande was a partner of MCM Capital Management, LLC, the general partner of MMI Investments, LP, a small-cap investment fund founded in 1996 to employ private equity investing methodologies in public equities, and where Mr. Lande oversaw research, trading, and activism from 1998 to 2011. During that time, he was also associated with MCM’s private equity investments wherein he was directly involved with corporate development as well as equity growth. Mr. Lande is a member of the board of directors and Chair of the Strategy Committee of CONMED Corporation, a public global medical technology company. Mr. Lande is also a member of the board of directors of Itron Inc., a public global technology company that offers products and services on energy and water resource management. He previously served as a member of the board of directors of Forest City Realty Trust, Inc., a public national real estate company.
Mr. Lande holds a B.A. from Cornell University. Under the provisions of the UK Corporate Governance Code, Jerome Lande will not be considered to be an independent Non-Executive Director, given his role representing Scopia on the Board.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide.
For more information: http://www.indivior.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
